Sangamo Therapeutics, Inc. announced that it has executed a global licensing collaboration agreement with Novartis to develop and commercialize gene regulation therapies to address three neurodevelopmental targets, including autism spectrum disorder and other neurodevelopmental disorders.
[Sangamo Therapeutics]
